1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 08 JUNE 2015

CNS Drug News 08 JUNE 2015

  • June 2015
  • -
  • Espicom Business Intelligence
  • -
  • 24 pages

Industry Trend Analysis - Global CINV Drugs Market On Course To Grow
Industry Brief - Biotie/FDA Reach SPA Agreement On Tozadenant Phase III PD Study
Industry Brief - Cynapsus Granted US Patent Providing Coverage For Sublingual Apomorphine
Industry Trend Analysis - Phase III Success Will Make vTv A Target
Industry Brief - Actavis Launches Namzaric
Industry Brief - Aphios Granted US Patent For AD Treatment
Industry Brief - Par Gains Appellate Court Success In Rivastigmine Patch Litigation
Industry Brief - EIP Reports First Patient Dosing In Phase II Studies Of VX-745 For AD
Industry Brief - Appeals Court Ruling Compels Continued Namenda Distribution
Industry Brief - Genzyme To Collaborate With Ablynx On MS Research Project
Industry Brief - Quebec Government To Cover Tecfidera As A First-Line Oral Treatment For MS
Industry Brief - Patient Enrolment Completed In Phase IIa Study Of RHB-104 For MS
Industry Brief - Horizon Initiates Phase III Trial Of Actimmune For FA
Industry Brief - FDA Grants ODD To MN-166 For Krabbe Disease
Industry Brief - FDA Clears Q Therapeutics' IND For Phase I/IIa Trials With Q-Cells In ALS
Industry Brief - Eisai Submits Ultra-High Dose Mecobalamin NDA In Japan For ALS
Industry Brief - Retrophin's RE-024 Receives FDA Fast Track Designation For PKAN
Industry Brief - Dr Reddy's Launches Somazina For Stroke Patients In India
Industry Brief - Edge Receives FDA ODD For EG-1962
Industry Brief - SanBio Granted Key Patent In New Treatment For Chronic Stroke
Industry Trend Analysis - More Provigil Rulings Will Dent Teva's Profits
Industry Brief - Positive Results For Latuda In First Placebo-Controlled Trial Of MDD Patients With Mixed Features
Industry Brief - Companies Gain US Guanfacine Approvals
Industry Brief - Rhodes Launches Aptensio XR In US For ADHD
Industry Brief - Neos Announces Trade Name Cotempla XR-ODT
Industry Brief - Highland Granted US Patents And NoA Covering HLD-200/HLD-100
Industry Brief - FDA Accepts Dyanavel XR NDA For Review In ADHD
Industry Brief - Cymbalta Approved In Japan For Pain Associated With Fibromyalgia
Industry Brief - FDA Grants Fast Track Designation For Intellipharmaceutics' Abuse-Deterrent Rexista Oxycodone XR
Industry Brief - ANI Gains US Oxycodone Approval
Industry Brief - PAION Initiates Further US Phase III Trial Of Remimazolam
Industry Brief - Trevena Granted Key US Composition Of Matter Patent For TRV734
Industry Trend Analysis - Probuphine On Course For FDA Approval In H116
Industry Brief - FDA Approves Expanded Indication For Qudexy XR Within The Paediatric Population
Industry Brief - Fycompa Gains Positive CHMP Opinion For PGTC Seizures
Industry Trend Analysis - Generic Contrave Will Be Worthwhile For Actavis Despite Modest Market
Industry Brief - Aloxi Gains EU Approval For CINV Prevention In Infants
Industry Brief - Ono Seeks Japanese Additional Approval For Proemend In CINV
Industry Brief - Otonomy Reports Phase IIb Top-Line Data For OTO-104 In Meniere's Disease
Industry Brief - Heron Reports Positive Results From Phase III MAGIC Study Of Sustol
Industry Brief - UCB Exercises Option To License Programme From Oncodesign Targeting Neurological Diseases
Industry Brief - BDSI Raises Funds For Bunavail Commercialisation

Table Of Contents

CNS Drug News 08 JUNE 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Alcoholism and drug dependence and addiction, known as substance use disorders and rehabilitation treatments are classified as substance abuse treatment. Some of the common symptoms of drug abuse are ...

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Psychotherapeutic drugs are used to treat mental illnesses such as extreme mood swings, social withdrawal, long lasting depression, confused thinking, and suicidal thought. schizophrenia, bipolar disorder, ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.